All manuscripts
Videos

Evolution of Tumor-specific T Cell Production

Share
ScaleReady Webinar and Video Content

What this paper found

This video features Juan Vera, Chief Development Officer at Marker Therapeutics, discussing how Marker used G-Rex® Bioreactors and the Lovo Cell Processing System to evolve and simplify manufacturing of its multiple tumor-associated antigen (MultiTAA) T cell therapy in anticipation of commercialization. This ScaleReady-sponsored seminar originally aired at the CAR-TCR Virtual 2021 Conference (Hanson Wade) on September 1st, 2021.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →